Generic Low-Molecular-Weight Heparins: Some Practical Considerations

 

 Buy Article Permissions and Reprints

ABSTRACT

It is now widely accepted that various low-molecular-weight heparins (LMWHs) exhibit specific molecular and structural attributes that are determined by the type of manufacturing process used. For example, enoxaparin, which is prepared by benzylation followed by alkaline hydrolysis of unfractionated heparin (UFH), exhibits a double bond at the nonreducing end and the presence of a unique bicyclic structure namely 1,6 anhydromanno glucose or mannose, or both, at the reducing end. Similarly, the other LMWHs, such as dalteparin, nadroparin, tinzaparin, and parnaparin, exhibit specific structural characteristics that may contribute to their own unique biochemical and pharmacological profiles. These unique features may not exhibit any major influence on the routinely determined anti-Xa and anti-IIa activities. However, these may have an impact on the pharmacokinetics and other biological actions such as the interactions with growth factors, blood components, and vascular cells. This is the reason for the initial caution for the noninterchangeability of the anti-Xa adjusted dosing of the different LMWHs. Although the nonanticoagulant biological effects of these drugs are poorly understood at this time, they are now recognized as contributing significantly to the overall therapeutic effects of these drugs. Because some of these drugs have proved to be effective in the management of cancer-associated thrombosis and exhibit improvements in mortality outcome, these LMWHs may also produce several other effects by modulating inflammatory processes, apoptosis, and other regulatory functions related to cellular functions at different levels. Thus, the interactions of these LMWHs with antithrombin and heparin cofactor II are not the only determinants of their biological actions. Release of tissue factor pathway inhibitor (TFPI), regulation of cytokines, nitric oxide, and eicosanoids contribute to their individuality. Such properties are not only dependent on the oligosaccharide sequence and consensus sites but also depend mainly on microchemical and structural attributes in these drugs. European Pharmacopoeia (EP) and the World Health Organization (WHO) have developed guidelines to characterize these agents in terms of their molecular and biological profile. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMEA) consider each of these drugs as distinct pharmacological agents. This has prompted the requirement for product-specific clinical data for the approval of their use in various clinical indications. There is a clear concern regarding the development of potential generic versions of branded products and the submissions by generic manufacturers for the regulatory approval of generic interchangeability that refers to the substitution of an apparent chemically identical and bioequivalent versions of the branded LMWHs. Currently, there are no regulatory guidelines or consensus opinions on the acceptance of generic versions of the branded products. Because the LMWHs represent not only a biological entity but also product-specific molecular and structural attributes, the acceptance of a generic version must be based on clearly defined guidelines stipulating minimal molecular and structural, biological, and clinical validation requirements. It is therefore to be stressed that each of the LMWHs is a distinct drug entity that characteristically exhibits a product-based therapeutic spectrum in different thrombotic and nonthrombotic disorders. Thus, until the establishment of valid regulatory guidelines for the generic interchangeability of the commercially available LMWHs is completed, generic substitutes are not recommended.

REFERENCES

• 1 Merli G, Vanscoy G J, Rihn T L et al.. Applying scientific criteria to therapeutic interchange: A balanced analysis of low molecular weight heparins.  J Thromb Thrombolysis. 2001;  11 247-259
  CrossrefPubMedGoogle Scholar
• 2 American Society of Hospital Pharmacists . ASHP statement on the formulary system.  Am J Hosp Pharm. 1986;  43 2839-2841
  PubMedGoogle Scholar
• 3 McCart G M, Kayser S. Therapeutic equivalency of low molecular weight heparins.  Ann Pharmacother. 2002;  36 1042-1057
  PubMedGoogle Scholar
• 4 Prandoni P. Low molecular weight heparins: are they interchangeable? Yes.  J Thromb Haemost. 2003;  1 10-11
  CrossrefPubMedGoogle Scholar
• 5 Nenci G. Low molecular weight heparins: are they interchangeable? No.  J Thromb Haemost. 2003;  1 12-13
  PubMedGoogle Scholar
• 6 Bick R L, Fareed J. Low molecular weight heparin: differences and similarities in approved preparations in the United States.  Clin Appl Thromb Hemost. 1999;  5(Suppl 1) S63-S66
  PubMedGoogle Scholar
• 7 Fareed J, Hoppensteadt D, Jeske W, Clarizio R, Walenga J M. Low molecular weight heparins. Are they different?.  Can J Cardiol. 1998;  14(Suppl E) 28E-34E
  PubMedGoogle Scholar
• 8 Leong W, Hoppensteadt D. Generic forms of low molecular weight heparins: some practical considerations.  Clin Appl Thromb Hemost. 2003;  9 293-297
  PubMedGoogle Scholar
• 9 Linhardt R J, Gunay N S. Production and chemical processing of low molecular weight heparins.  Semin Thromb Hemost. 1999;  25(Suppl 3) 5-16
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 Nightingale S L. From the Food and Drug Administration.  JAMA. 1993;  270 1672
  CrossrefPubMedGoogle Scholar
• 11 Hirsh J, Warkentin T E, Raschke R et al.. Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.  Chest. 1998;  114(Suppl 5) 489S-510S
  PubMedGoogle Scholar
• 12 Ryan T J, Antman E M, Brooks N H et al.. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) J Am Coll Cardiol 1999 34: 890-911
  Google Scholar
• 13 Fareed J, Fu K, Yang L H et al.. Pharmacokinetics of low molecular weight heparins in animal models.  Semin Thromb Hemost. 1999;  25(suppl 3) 51-55
  PubMedGoogle Scholar
• 14 Kaiser B, Kirchmaier C M, Breddin H K et al.. Pre-clinical biochemistry and pharmacology of low molecular weight heparins in vivo.  Semin Thromb Hemost. 1999;  25(suppl 3) 35-42
  PubMedGoogle Scholar
• 15 Cohen M, Demers C, Gurfinkel E P et al.. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in non-Q wave Coronary Events (ESSENCE) Group.  N Engl J Med. 1997;  337 447-452
  CrossrefPubMedGoogle Scholar
• 16 Klein W, Buchwald A, Hillis W S et al.. Fragmin in unstable angina pectoris or in non-Q wave acute myocardial infarction. Fragmin in unstable coronary artery disease (FRIC).  Am J Cardiol. 1997;  80 30E-34E
  CrossrefPubMedGoogle Scholar
• 17 FRISC Study Group . Low molecular weight heparin during instability in coronary artery disease.  Lancet. 1998;  34 561-568
  PubMedGoogle Scholar
• 18 Mousa S, Fareed J. Overview: from heparin to low molecular weight heparins: beyond anticoagulation.  Curr Opin Invest Drug. 2001;  2 1077-1080
  PubMedGoogle Scholar
• 19 Fareed J, Kumar A, Walenga J M et al.. Antithrombotic actions and pharmacokinetics of heparin fractions and fragments.  Nouv Rev Fr Hematol. 1984;  26 267-275
  PubMedGoogle Scholar
• 20 Fareed J, Walenga J M, Racanelli A et al.. Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins.  Haemostasis. 1988;  18(suppl 3) 33-47
  PubMedGoogle Scholar
• 21 Barrett J S, Hainer J W, Kornhauser D M et al.. Anticoagulant pharmacodynamics of tinzaparin following 175 IU/kg subcutaneous administration to healthy volunteers.  Thromb Res. 2001;  101 243-254
  CrossrefPubMedGoogle Scholar
• 22 Fareed J, Haas S, Sasahara A Differentiation of low molecular weight heparins: applied and clinical considerations. Semin Thromb Hemost 1999 25(suppl 3): 1-147
  Google Scholar
• 23 Fareed J, Walenga J M, Hoppensteadt D, Huan X, Racanelli A. Comparative studies on the in vitro and in vivo activities of seven low-molecular-weight heparins.  Haemostasis. 1988;  18(suppl 3) 3-15
  PubMedGoogle Scholar
• 24 Fareed J, Walenga J M, Williamson K et al.. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments.  Semin Thromb Hemost. 1985;  11 56-74
  PubMedGoogle Scholar
• 25 Memorandum on a provisional international standard for heparin . Bull Health Organization League of Nations.  1942;  151-154
  Google Scholar
• 26 Barrowcliffe T W, Curtiss A D, Johnson E A, Thomas D P. An international standard for low molecular weight heparin.  Thromb Haemost. 1988;  60 1-7
  PubMedGoogle Scholar
• 27 Mulloy B, Gee C, Wheeler S F et al.. Molecular weight measurements of low molecular weight heparins by gel permeation chromatography.  Thromb Haemost. 1997;  77 668-674
  PubMedGoogle Scholar
• 28 Cambus J P, Saivin S, Heilmann J J et al.. The pharmacodynamics of tinzaparin in healthy volunteers.  Br J Haematol. 2002;  116 649-653
  CrossrefPubMedGoogle Scholar
• 29 Abboud L. Bush acts to speed generics to market.  The Wall Street Journal . June 12, 2003;  p A3
  PubMedGoogle Scholar

Jawed FareedPh.D.  Professor

Department of Pathology, Loyola University Chicago

2160 S. First Avenue, Maywood, IL 60153

Email: jfareed@lumc.edu